Details for Patent: 8,680,052
✉ Email this page to a colleague
Which drugs does patent 8,680,052 protect, and when does it expire?
Patent 8,680,052 protects KENGREAL and is included in one NDA.
This patent has fifty-seven patent family members in seventeen countries.
Summary for Patent: 8,680,052
Title: | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Abstract: | Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y.sub.12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality. |
Inventor(s): | Arculus-Meanwell; Clive Arthur (Bernardsville, NJ), Skerjanec; Simona (Basel, CH), Prats; Jayne (Carlisle, MA), Schneider; David J. (Colchester, VT) |
Assignee: | The Medicines Company (Parsippany, NJ) |
Application Number: | 13/904,778 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,680,052 |
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 8,680,052
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chiesi | KENGREAL | cangrelor | POWDER;INTRAVENOUS | 204958-001 | Jun 22, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | METHOD COMPRISING IV ADMINISTRATION OF CANGRELOR BEFORE PCI THEN CONTINUOUS INFUSION FOR AT LEAST 2 HOURS OR THE DURATION OF PCI AND, DURING OR AFTER CONTINUOUS INFUSION, ADMINISTRATION OF A LOADING DOSE OF TICAGRELOR, OR AN EQUIVALENT METHOD | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,680,052
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2009246396 | ⤷ Try a Trial | |||
Australia | 2010319612 | ⤷ Try a Trial | |||
Australia | 2012295343 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |